Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated by Analysts at StockNews.com

by · The Markets Daily

StockNews.com began coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a report issued on Saturday morning. The brokerage issued a hold rating on the stock.

Several other equities research analysts also recently weighed in on ONCT. Northland Capmk downgraded shares of Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 12th. Brookline Capital Management restated a “hold” rating on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. Finally, Northland Securities reaffirmed a “market perform” rating and set a $2.00 price target on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $10.00.

Get Our Latest Stock Analysis on ONCT

Oncternal Therapeutics Price Performance

Shares of ONCT stock opened at $0.53 on Friday. The firm has a 50 day moving average of $1.06 and a 200-day moving average of $3.68. The company has a market cap of $1.56 million, a price-to-earnings ratio of -0.05 and a beta of 1.18. Oncternal Therapeutics has a 52 week low of $0.53 and a 52 week high of $13.14.

About Oncternal Therapeutics

(Get Free Report)

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.

Recommended Stories